RET and medullary thyroid gland carcinoma: Our cohort study of genomic screening of more than 500 000 unselected individuals from 2 different ascertainment settings suggests that incidental pathogenic activating RET variants occurred in approximately 1 in 2000 individuals, 30-fold more common than previously estimated.23 The majority were moderate-risk variants associated with low medullary thyroid cancer risk and no excess in all-cause mortality without thyroidectomy.